Tecan Group AG (TCGGY) Research

Tecan Group AG delivers advanced laboratory instruments and complete solutions to a diverse client base, including pharmaceutical and biotechnology companies, academic research institutions, and both forensic and diagnostic laboratories. The company operates through two primary segments: Life Sciences Business and Partnering Business. Its comprehensive product range features liquid handling and automation systems, microplate readers and washers, various consumables, next-generation sequencing (NGS) reagents, immunoassays, microbodies, and specialized software. Key offerings include Tecan Laberwax, an innovative automation solution, and Resolvex, an intelligent sample preparation system utilized in fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions. Furthermore, Tecan develops and manufactures essential components like precision pumps, valves, robotic arms, and developer software, supplying these to other laboratory instrument manufacturers for use in life science research, diagnostics, and other industries. Its automation portfolio also includes platforms like Synergence and renowned instruments such as Freedom EVO and Fluent. With a global presence, Tecan Group AG conducts operations across Switzerland, Europe, North America, Asia, and other international markets. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.

Market snapshot

Symbol
TCGGY
Price
$36.00
Day change
0.00%
Market cap
$1.9B
P/E ratio
-17.37x
52-week range
36-38.38
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • Alfresa Holdings Corporation (ALFRY)
  • Ansell Limited (ANSLY)
  • GN Store Nord A/S (GGNDF)
  • GN Store Nord A/S (GNNDY)
  • Haw Par Corporation Limited (HAWPF)
  • HUTCHMED (China) Limited (HMDCF)
  • Embla Medical hf. (OSSFF)
  • Embla Medical hf. (OSSUY)

Open Tecan Group AG (TCGGY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.